To hasten release pfizer vaccine docs1/18/2024 If the vaccine is authorized, hospitals, pharmacies and other health centers will have to be ready to handle the doses properly. Most importantly, Pfizer says it fulfilled the FDA’s safety requirement of following most of the study participants for two months to ensure they did not experience serious side effects or adverse events. Read more: Why You May Not Be Able to Get Pfizer’s Frontrunner COVID-19 Vaccine There was encouraging data that the vaccine also protected against severe disease-of the 10 people in the trial who experienced severe COVID-19, only one had received the vaccine the rest had gotten a placebo. The vaccine was equally effective in older as well as younger people the shot was 94% effective in protecting against COVID-19 illness among those over age 65. Just eight people who had received the two-dose vaccine got sick with COVID-19. In the new written release, Pfizer said its full data report involved more than 43,000 study participants and logged 170 cases of COVID-19-162 of which occurred among people receiving the placebo shot. Pfizer and BioNTech’s initial announcement included data from 94 cases of COVID-19 among both the vaccinated and placebo groups in the Phase 3 study. The newly released data from Pfizer shows similar efficacy. Moderna then reported a week later that its vaccine was 94.5% effective. 9, noted that it was more than 90% effective in protecting people from symptomatic COVID-19 disease. New York-based Pfizer, which partnered with German biotech BioNTech, was the first to report results from its Phase 3 study of a pandemic vaccine.
0 Comments
Leave a Reply.AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |